Akèy › Kondisyon Post-COVID (Long COVID)
Etid klinik pou Kondisyon Post-COVID (Long COVID) ap rekrite nan Etazini
118 etid pou Kondisyon Post-COVID (Long COVID) ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- New York City, NY15 etid
- Houston, TX13 etid
- Boston, MA13 etid
- Baltimore, MD12 etid
- Chicago, IL11 etid
- Washington, DC10 etid
- San Francisco, CA8 etid
- Atlanta, GA8 etid
- Durham, NC8 etid
- San Diego, CA7 etid
- Hialeah, FL6 etid
- Miami, FL6 etid
- Los Angeles, CA6 etid
- Salt Lake City, UT6 etid
- Pittsburgh, PA6 etid
- Dallas, TX5 etid
- Columbus, OH5 etid
- Mountain View, CA4 etid
- St. Louis, MO4 etid
- Tampa, FL4 etid
- Louisville, KY4 etid
- San Antonio, TX4 etid
- Cincinnati, OH4 etid
- Seattle, WA4 etid
- Birmingham, AL4 etid
- Nashville, TN4 etid
- Austin, TX3 etid
- Sacramento, CA3 etid
- Kendall, FL3 etid
- Omaha, NE3 etid
- Warren, MI3 etid
- Boise, ID3 etid
- Charleston, SC3 etid
- St. Petersburg, FL3 etid
- Homestead, FL3 etid
- The Woodlands, TX3 etid
- New Orleans, LA3 etid
- Portland, OR3 etid
- New Haven, CT3 etid
- Philadelphia, PA3 etid
Pa eta
- Alabama7 etid
- Arizona4 etid
- Colorado6 etid
- Connecticut3 etid
- Distrik Columbia4 etid
- Florid13 etid
- Georgia11 etid
- Idaho3 etid
- Illinois13 etid
- Iowa3 etid
- Kalifòni30 etid
- Kansas3 etid
- Kentucky6 etid
- Lwizyàn7 etid
- Maryland21 etid
- Massachusetts13 etid
- Michigan6 etid
- Minnesota6 etid
- Missouri4 etid
- Nebraska3 etid
- Nevada4 etid
- New Jersey3 etid
- New York18 etid
- North Carolina10 etid
- Ohio11 etid
- Oregon3 etid
- Pennsylvania11 etid
- South Carolina4 etid
- Tennessee8 etid
- Texas23 etid
- Utah7 etid
- Virginia6 etid
- Washington5 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 64 · Tout sèks · Mizajou Oct 2, 2026 · NCT07536308Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT05624450Exercise in Child Health
Ap rekriteVolontè an sante akeyi
Laj 10 a 17 · Tout sèks · Mizajou Oct 2, 2026 · NCT05359991Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06160128SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Sep 29, 2026 · NCT07021794Long-Term Study of COVID-19 Infection and Long COVID
Ap rekriteEtid obsèvasyon
Laj 18 a 75 · Tout sèks · Mizajou Sep 28, 2026 · NCT07781501Heat thErapy And mobiLity in COVID-19 Survivors
Ap rekrite
Laj 50 a 90 · Tout sèks · Mizajou Sep 28, 2026 · NCT06928116A Study of COVID-19 Vaccine(s) in Children and Adults
Ap rekriteFaz 3Volontè an sante akeyi
Laj 5 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07798648A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
Ap rekriteFaz 3
Laj 12 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06679140A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07013474Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06631287A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06667700A Study to Examine Anktiva for the Treatment of COVID-19.
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT07123727A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease
Ap rekriteFaz 3
Laj 12 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT07743580Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 110 · Tout sèks · Mizajou Sep 16, 2026 · NCT06577467Piloting Virtual Reality Environments to Treat PTSD in Healthcare Workers
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT04887116Viral Infections in Healthy and Immunocompromised Hosts
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
6 Months – 120 Years · Tout sèks · Mizajou Sep 14, 2026 · NCT01306084A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 64 · Tout sèks · Mizajou Sep 10, 2026 · NCT07445971Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health
Ap rekriteEtid obsèvasyon
Laj 18 a 100 · Tout sèks · Mizajou Sep 9, 2026 · NCT04573062Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
1 Day – 99 Years · Tout sèks · Mizajou Sep 9, 2026 · NCT04582903Long-Covid-19 Alleviation Through Learning Mindfulness Study
Ap rekriteVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Aug 31, 2026 · NCT07140094Dime La VerDAD: Verify, Debunk, and Disseminate
Ap rekriteVolontè an sante akeyi
Laj 18 a 99 · Tout sèks · Mizajou Aug 26, 2026 · NCT06417762Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 0 a 20 · Tout sèks · Mizajou Aug 21, 2026 · NCT04278404Validation of Biomarkers for Long COVID in the LIINC Viral Immunopathogenesis and Persistence Repeat Donor Cohort (VIPER)
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT07770022A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
Ap rekriteFaz 1/2Volontè an sante akeyi
Laj 40 a 64 · Tout sèks · Mizajou Aug 18, 2026 · NCT06810934Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.